Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Company Drug

NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination

Fineline Cube Jun 5, 2025

Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...

Company Deals

SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round

Fineline Cube Jun 5, 2025

Shanghai-based SciBrunch Therapeutics, a developer of small molecule anti-tumor drugs, has reportedly secured over RMB...

Company Drug

JW Therapeutics’ Carteyva Approved by Macau Health Bureau

Fineline Cube Jun 5, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Deals

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Fineline Cube Jun 5, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the successful placement of 5,918,000 new...

Company Deals

Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa

Fineline Cube Jun 5, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...

Company Drug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease

Fineline Cube Jun 4, 2025

France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD)...

Company Drug

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Fineline Cube Jun 4, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the Phase III clinical study of its...

Company Deals Drug

Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products

Fineline Cube Jun 4, 2025

US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...

Company Drug

CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials

Fineline Cube Jun 4, 2025

China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...

Company Medical Device

Bio-heart Launches Iberis Renal Ablation System at OCC 2025

Fineline Cube Jun 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...

Company Deals

BioAge Labs Partners with JiKang for APJ Agonist Nanobody License

Fineline Cube Jun 4, 2025

US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...

Company Drug

Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment

Fineline Cube Jun 4, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration...

Company Deals

Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer

Fineline Cube Jun 4, 2025

Sainte Nutritional Inc., China’s leading provider of Food for Special Medical Purpose (FSMP), has filed...

Company Drug

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...

Company Deals

Harbin Gloria Partners with Eisai to Promote Methycobal in China

Fineline Cube Jun 4, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service...

Company Drug

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Jun 4, 2025

Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...

Company Drug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Fineline Cube Jun 4, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...

Company Drug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

Fineline Cube Jun 4, 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...

Company Medical Device Policy / Regulatory

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Fineline Cube Jun 4, 2025

China Central Television (CCTV) reported that EU member states have voted under the International Procurement...

Company Drug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...

Posts pagination

1 … 197 198 199 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.